HOUSE No. 989

The Commonwealth of Massachusetts

PRESENTED BY:

Theodore C. Speliotis

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to Lyme Disease treatment coverage.

PETITION OF:

NAME:	DISTRICT/ADDRESS:	DATE ADDED:
Theodore C. Speliotis	13th Essex	1/17/2013
David Paul Linsky	5th Middlesex	
Daniel A. Wolf	Cape and Islands	
Timothy R. Madden	Barnstable, Dukes and Nantucket	
Sarah K. Peake	4th Barnstable	
William Smitty Pignatelli	4th Berkshire	
Bradford Hill	4th Essex	
Anne M. Gobi	5th Worcester	
Brian R. Mannal	2nd Barnstable	
Todd M. Smola	1st Hampden	
Ruth B. Balser	12th Middlesex	
Kay Khan	11th Middlesex	
Angelo J. Puppolo, Jr.	12th Hampden	
Josh S. Cutler	6th Plymouth	
Cleon H. Turner	1st Barnstable	
Eileen M. Donoghue	First Middlesex	
William N. Brownsberger	Second Suffolk and Middlesex	
Chris Walsh	6th Middlesex	

David M. Rogers	24th Middlesex	
Mary S. Keefe	15th Worcester	
John V. Fernandes	10th Worcester	
Christopher M. Markey	9th Bristol	
John J. Lawn, Jr.	10th Middlesex	
Jonathan D. Zlotnik	2nd Worcester	
Denise C. Garlick	13th Norfolk	
Stephen L. DiNatale	3rd Worcester	
Paul K. Frost	7th Worcester	
Thomas M. McGee	Third Essex	
Ellen Story	3rd Hampshire	
Michael J. Rodrigues	First Bristol and Plymouth	
James E. Timilty	Bristol and Norfolk	
Robert F. Fennell	10th Essex	
Sheila C. Harrington	1st Middlesex	
Tom Sannicandro	7th Middlesex	
Thomas M. Stanley	9th Middlesex	
Marjorie C. Decker	25th Middlesex	
Sean Garballey	23rd Middlesex	

HOUSE No. 989

By Mr. Speliotis of Danvers, a petition (accompanied by bill, House, No. 989) of Theodore C. Speliotis and others relative to Lyme Disease treatment coverage. Financial Services.

[SIMILAR MATTER FILED IN PREVIOUS SESSION SEE HOUSE, NO. 329 OF 2011-2012.]

The Commonwealth of Alassachusetts

In the Year Two Thousand Thirteen

An Act relative to Lyme Disease treatment coverage.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

SECTION 1. Chapter 111, as appearing in the 2010 Official Edition, is hereby amended by inserting, after section 218, the following new sections:

SECTION 219. Every individual or group hospital or medical expense insurance policy or individual or group hospital or medical services plan contract delivered, issued for delivery or renewed in this state on or after January 1, 2010, shall provide for Lyme disease treatment.

SECTION 220. Every individual or group hospital or medical expense insurance policy or individual or group hospital or medical services plan contract delivered, issued for delivery or renewed in this state on or after January 1, 2010, shall provide coverage for diagnostic testing and long-term antibiotic treatment of chronic Lyme disease when determined to be medically necessary and ordered by a physician after making a thorough evaluation of the patient's symptoms, diagnostic test results and response to treatment. Treatment otherwise eligible for benefits pursuant to this section shall not be denied solely because such treatment may be characterized as unproven, experimental, or investigational in nature. Provided, however, this section shall not apply to insurance coverage providing benefits for:

- 15 Hospital confinement indemnity;
- Disability income;

1

2

3

4

5

6

7

8

9

10

1112

13

14

17 Accident only; 18 Long-term care; 19 Medicare supplement; 20 Limited benefit health; 21 Specified disease indemnity; 22 Sickness or bodily injury or death by accident or both; and 23 Other limited benefit policies. 24 Section 221. Subscribers to any health maintenance organization plan shall be afforded 25 coverage under that plan on or after January 1, 2010 for diagnostic testing and long term 26 antibiotic treatment of chronic Lyme disease when determined to be medically necessary and 27 ordered by a physician after making a thorough evaluation of the patient's symptoms, diagnostic 28 test results and response to treatment. Treatment otherwise eligible for benefits pursuant to this 29 section shall not be denied solely because such treatment may be characterized as unproven, 30 experimental, or investigational in nature.